RxDoctor Payments Data

Ata Kashani, MD

Family Medicine · Reseda, CANPI 1740349851

Payments from drug & device makers

$1,836in general payments, 2019–2025

Across 83 payments — averaging $22.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$299
  • Amarin Pharma, Inc.$281
  • AstraZeneca$274
  • Boehringer Ingelheim$218
  • Lilly USA, LLC$183
  • Pfizer$99
  • plus $482 from 11 others

What the payments were for

  • Food & beverage$1,81599%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,836 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$102,086
Medicare patients
138
Services billed
1,391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide90$78,012
JanumetSitagliptin Phos/Metformin Hcl69$65,816
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$57,605
VascepaIcosapent Ethyl103$49,583
JardianceEmpagliflozin41$43,122
MounjaroTirzepatide25$41,584
Diclofenac Sodium182$35,230
MyrbetriqMirabegron42$33,491
ProliaDenosumab18$30,215
TrulicityDulaglutide26$28,113
EliquisApixaban18$17,508
Icosapent Ethyl67$17,259
Xigduo XrDapaglifloz Propaned/Metformin11$15,803
Dexlansoprazole DrDexlansoprazole64$13,027
XareltoRivaroxaban23$12,686

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$52$78,01290 claims
MerckJanumet, Januvia$38$76,48384 claims
Lilly USA, LLCMounjaro, Trulicity$183$69,69851 claims
GSKTrelegy Ellipta$78$57,60563 claims
Boehringer IngelheimJardiance$218$43,12241 claims
AmgenProlia$299$30,21518 claims
PfizerEliquis$99$17,50818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Reseda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →